Skip to content
Peptidepedia

Selank Side Effects: Safety Profile, Risks & What to Expect (2026)

From Peptidepedia, the trusted peptide wiki.

Side Effects

Selank has one of the cleanest side effect profiles of any anxiolytic compound studied in clinical settings. This tolerability advantage over benzodiazepines and SSRIs is consistently highlighted across Russian clinical literature.

Commonly Reported (Intranasal):

  • Mild stinging or irritation in nasal passages (transient, resolves within minutes)
  • Nasal dryness with repeated daily use
  • Mild taste or odor disturbance immediately after administration

Uncommonly Reported:

  • Headache (mild, typically with higher doses)
  • Dizziness (transient)
  • Fatigue (paradoxical, reported rarely)

Notably Absent:

  • Sedation or drowsiness (consistently absent across clinical comparisons)
  • Cognitive impairment or psychomotor slowing
  • Tolerance development within standard 14-day courses
  • Physical dependence or withdrawal symptoms upon cessation
  • Rebound anxiety after treatment discontinuation
  • Muscle relaxation or ataxia

Serious Adverse Events: No serious adverse events have been attributed to Selank in published clinical literature. The FDA has raised a general immunogenicity concern regarding compounded peptide products, the theoretical risk that the body could mount an immune response against the peptide, but no cases of immunogenicity-related adverse events from Selank have been published.

Sourcing Risks: As with all unregulated peptides, individuals sourcing Selank from research chemical suppliers face contamination, degradation, and mislabeling risks that are distinct from the compound's intrinsic safety profile. Third-party certificate of analysis verification is essential.

Frequently Asked Questions

The most common intranasal protocol is 200 to 400 mcg administered two to three times daily. Russian clinical studies used 250 to 300 mcg intranasal doses in 14-day courses. Daily doses up to 1,000 mcg have been used without reported adverse effects, though doses above 300 mcg are typically split across multiple administrations.

Selank has a notably clean side effect profile. The most commonly reported effects are mild nasal irritation, transient stinging, or dryness at the administration site. Unlike benzodiazepines, Selank does not cause sedation, cognitive impairment, tolerance, or dependence in published clinical data.

This content is for educational and informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making any health-related decisions.

References

  1. Zozulya AA, Sizov SV, Syrtsev AV. Efficacy and possible mechanisms of action of a new peptide anxiolytic selank in the therapy of generalized anxiety disorders and neurasthenia. Zh Nevrol Psikhiatr Im S S Korsakova. 2008;108(4):38-48.
  2. Kasian A, Kolomin T, Andreeva L, et al. Peptide Selank Enhances the Effect of Diazepam in Reducing Anxiety in Unpredictable Chronic Mild Stress Conditions in Rats. Behav Neurol. 2017;2017:5091027.
  3. Zozulya AA, Kost NV, Sokolov OY, et al. A comparison of the anxiolytic effect and tolerability of selank and phenazepam in the treatment of anxiety disorders. Zh Nevrol Psikhiatr Im S S Korsakova. 2014;114(7):17-22.
  4. Volkova A, Shadrina M, Kolomin T, et al. Selank Administration Affects the Expression of Some Genes Involved in GABAergic Neurotransmission. Front Pharmacol. 2016;7:31.
  5. Andreeva LA, Kolomin TA, Myasoedov NF. GABA, Selank, and Olanzapine Affect the Expression of Genes Involved in GABAergic Neurotransmission in IMR-32 Cells. Front Pharmacol. 2017;8:89.
  6. Kolomin T, Shadrina M, Slominsky P, et al. Expression of inflammation-related genes in mouse spleen under tuftsin analog Selank. Regul Pept. 2011;170(1-3):18-23.
  7. Kolomin T, Morozova M, Shadrina M, et al. The temporary dynamics of inflammation-related genes expression under tuftsin analog Selank action. Mol Immunol. 2014;58(1):50-55.
  8. Myasoedov NF, Andreeva LA, Grigorjeva ME, et al. Peptide-based Anxiolytics: The Molecular Aspects of Heptapeptide Selank Biological Activity. Protein Pept Lett. 2018;25(10):914-923.
  9. World Anti-Doping Agency. The 2026 Prohibited List: International Standard.
  10. US Food and Drug Administration. Certain Bulk Drug Substances for Use in Compounding That May Present Significant Safety Risks.
←Read the full Selank guide

“Peptidepedia compiles and maintains peptide information from peer-reviewed research, clinical trials, and verified laboratory data.”